tadalafil has been researched along with dehydroepiandrosterone sulfate in 1 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (dehydroepiandrosterone sulfate) | Trials (dehydroepiandrosterone sulfate) | Recent Studies (post-2010) (dehydroepiandrosterone sulfate) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 4,127 | 412 | 946 |
| Protein | Taxonomy | tadalafil (IC50) | dehydroepiandrosterone sulfate (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baldari, C; Bianchini, S; Di Luigi, L; Emerenziani, GP; Gallotta, MC; Guidetti, L; Lenzi, A; Pigozzi, F; Romanelli, F; Sgrò, P | 1 |
1 trial(s) available for tadalafil and dehydroepiandrosterone sulfate
| Article | Year |
|---|---|
The type 5 phosphodiesterase inhibitor tadalafil influences salivary cortisol, testosterone, and dehydroepiandrosterone sulphate responses to maximal exercise in healthy men.
Topics: Adult; Carbolines; Cross-Over Studies; Dehydroepiandrosterone Sulfate; Double-Blind Method; Exercise; Health; Humans; Hydrocortisone; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Placebos; Saliva; Stress, Physiological; Tadalafil; Testosterone | 2008 |